Physician profile
Charles D Register
NPI 1053493361
$1,633.71
in general payments reported to CMS, 2019-2025
12 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $15.06 · 2021: $274 · 2022: $451 · 2023: $216 · 2024: $250 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $557.71 | 2021-2025 | Clareon Panoptix Pro, Clareon, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $260.93 | 2019-2021 | |
| Allergan, INC. | $230.60 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $140.00 | 2023-2024 | Xiidra, Miebo, Infuse |
| Oyster Point Pharma, INC. | $122.63 | 2022 | |
| Dompe US, INC. | $98.80 | 2023 | Oxervate |
| Aerie Pharmaceuticals, INC. | $92.02 | 2019 | |
| Coopervision INC. | $61.40 | 2022-2024 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $21.58 | 2023 | Acuvue |
| Biotissue Holdings INC. | $18.09 | 2022 | |
| Sight Sciences, INC. | $16.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Register listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.